EPA:ABVX.PA 10 December 2025

Abivax stock jumps on fresh Eli Lilly takeover talk as ABVX.PA hits record — what traders watch next

Abivax shares jumped 22% to 120.60 euros Monday after French outlet La Lettre reported Eli Lilly is preparing a 15 billion euro takeover bid. CEO Marc de Garidel dismissed the rumors, saying the company is focused on drug development. Neither Abivax nor Lilly commented. Investors await statements at the JPMorgan Healthcare Conference this week.

12 January 2026

EPA:ABVX.PA·Stock Market

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax shares fell 9.49% to 99.20 euros in Paris on Thursday, reversing a 6% gain from the previous day. Volume reached about 246,000 shares amid anticipation of Phase 3 trial results for obefazimod in late Q2 2026. A U.S. Form 144 filing showed Sofinnova Crossover I SLP intends to sell up to 1,000,000 ADS. BTIG raised its price target on Abivax to $150 and maintained a “Buy” rating.

8 January 2026

EPA:ABVX.PA·Stock Market

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax shares surged as much as 20% on December 10, 2025, in Paris trading amid market rumors of a possible takeover bid by Eli Lilly. The stock hit a 52-week high near €126.60, with market value reaching about €9.7 billion. Abivax declined to comment, and no formal offer has been announced. U.S.-listed ADRs also jumped over 11% in pre-market trading.

10 December 2025

EPA:ABVX.PA·Mergers & Acquisitions·NASDAQ:ABVX·NYSE:LLY·Stock Market

RTX Shares See 52% Gain in Year - Is It Overvalued at $200?
March 20, 2026, 1:45 AM EDT. RTX's share price rose 51.8% over the past year but dropped 1.4% last month, trading around $200.73. A Discounted Cash Flow (DCF) analysis values RTX at $183.11, suggesting the stock is about 9.6% overvalued based on projected free cash flows. Despite promising aerospace and defense sector positioning, valuation signals are mixed, with a 3 out of 6 score indicating both undervaluation and fair pricing factors. Investors should watch RTX closely for market shifts and updates to fundamentals that could affect its value.